Synthetic FXR agonists, including steroidal and nonsteroidal ligands, for the treatment of liver diseases, such as nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), are currently under development. Here, NR1H4 is linked to primary biliary cholangitis.